Literature DB >> 2536017

Characterization of the cellular binding site for the urokinase-type plasminogen activator.

A Estreicher1, A Wohlwend, D Belin, W D Schleuning, J D Vassalli.   

Abstract

Human urokinase-type plasminogen activator (uPA) binds rapidly and with high affinity to a number of human cell types; this localizes plasmin generation to the close environment of the cell surface. uPA binding to HeLa and U937 cells is mediated by a single class of sites with an affinity of 3.4 +/- 1.3 x 10(-10) M. Binding is abolished by treatment of the cells with trypsin. Chemical cross-linking of Mr 55,000 125I-uPA to the surface of HeLa and U937 cells with disuccinimidyl suberate or with formaldehyde results in the formation of a labeled complex of Mr 100,000, suggesting a Mr of 45,000 +/- 5,000 for the receptor or a subunit thereof. When cells solubilized in Triton X-114 are subjected to heat-induced phase separation, unoccupied receptor, receptor-bound 125I-uPA, and cross-linked 125I-uPA-receptor complex all partition in the detergent phase, whereas the unbound ligand remains in the aqueous phase; similar phase partitioning is observed with endogenous uPA-receptor complexes from cultured human and murine cells. Thus, uPA bound at the cell surface is tightly associated with an amphiphilic membrane protein. Interaction of uPA with this plasma membrane receptor is species-specific, since human uPA fails to bind to murine cells, and murine uPA does not bind to human cells. Finally, incubation of HeLa cells in the presence of epidermal growth factor or phorbol 12-myristate 13-acetate results, over a period of 24 h, in a progressive change in uPA binding: an approximately 10-fold increase in the number of sites is accompanied by a 10-fold decrease in their affinity. Cross-linking and phase partitioning of 125I-uPA bound to epidermal growth factor- or phorbol 12-myristate 13-acetate-treated cells indicate that, as in control conditions, it is associated with a Mr 45,000 cell surface amphiphilic polypeptide.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536017

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.

Authors:  A M Henney; P R Wakeley; M J Davies; K Foster; R Hembry; G Murphy; S Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

4.  A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.

Authors:  Boryana M Eastman; Minji Jo; Drue L Webb; Shinako Takimoto; Steven L Gonias
Journal:  Cell Signal       Date:  2012-05-19       Impact factor: 4.315

5.  Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains.

Authors:  Philip G Massey; Shinji Tanaka; Joshua M Buckler; Bo Jiang; Anton McCourtie; Kun Qian; Clifford Tom; April Stempien-Otero; Shan Wen; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

6.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

7.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

9.  The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Authors:  Minji Jo; Shinako Takimoto; Valerie Montel; Steven L Gonias
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

10.  Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Authors:  Gretchen A Larusch; Alona Merkulova; Fakhri Mahdi; Zia Shariat-Madar; Robert G Sitrin; Douglas B Cines; Alvin H Schmaier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.